Skip to main content

TXG 10x Genomics, Inc.

Healthcare

quality needs a look, discounted valuation.

Quality
Weak
Valuation
Cheaper
Key signals
52-week adjusted-price high Top-quintile 6-month momentum
85.71
85.71 Close (USD) Loading candles…

Is 10x Genomics, Inc. a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 23th percentile. TTM ROE is about -9.1%.

  • Valuation is cheaper than most peers. TTM P/E is in the 2th percentile, lower than most liquid US common stocks.

  • Recent volatility is elevated. 60-day annualized volatility is in the 76th percentile. Average 20-day dollar volume is about $203.0M.

  • Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Watchlist

This page refreshes daily after the close. Add 10x Genomics, Inc. to your watchlist to track signal changes on your next visit.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

12 historical occurrences (since 2020-09-11)
Average forward return after 52-week adjusted-price high。20-day: Win 41.7%, Sample 12, Median -1.46%, Excess +1.41%, Beat mkt rate 41.7%；60-day: Win 58.3%, Sample 12, Median +10.74%, Excess +17.66%, Beat mkt rate 58.3%；120-day: Win 44.4%, Sample 9, Median -2.79%, Excess -1.14%, Beat mkt rate 33.3%

120 days after: historical avg +7.94%

20-day +3.26%
60-day +21.26%
120-day +7.94%
20-day
60-day
120-day
Win
41.7%
58.3%
44.4%
Sample
12
12
9
Median
-1.46%
+10.74%
-2.79%
Excess
+1.41%
+17.66%
-1.14%
Beat mkt rate
41.7%
58.3%
33.3%

Over 9 occurrences, 120-day forward avg gained 7.94%, lagged the market by 1.14 pts; win rate 44.4%.

Top-quintile 6-month momentum

Active · now 99.91503823279524%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

15 historical occurrences (since 2020-03-13)
Average forward return after Top-quintile 6-month momentum。20-day: Win 60%, Sample 15, Median +6.98%, Excess +4.4%, Beat mkt rate 53.3%；60-day: Win 80%, Sample 15, Median +24.21%, Excess +18.84%, Beat mkt rate 80%；120-day: Win 78.6%, Sample 14, Median +28.57%, Excess +31.62%, Beat mkt rate 64.3%

120 days after: historical avg +42.93%

20-day +5.77%
60-day +24.21%
120-day +42.93%
20-day
60-day
120-day
Win
60%
80%
78.6%
Sample
15
15
14
Median
+6.98%
+24.21%
+28.57%
Excess
+4.4%
+18.84%
+31.62%
Beat mkt rate
53.3%
80%
64.3%

Over 14 occurrences, 120-day forward avg gained 42.93%, beat the market by 31.62 pts; win rate 78.6%.

Market-wide momentum baseline

Across 98,702 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.12%, a 57.8% positive-return rate, and +2.76 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

7 times historically; 60-day forward avg -14.97%, win rate 28.6%, beating the market by -18.65 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

15 times historically; 60-day forward avg +15.16%, win rate 57.1%, beating the market by +11.53 pts on average.

Continue researching 10x Genomics, Inc. with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.